Exhibit 5.1

Andrew Abramowitz, PLLC
565 Fifth Avenue, 9^th Floor
New York, New York 10017

January 31, 2013

iBio, Inc.
9 Innovation Way, Suite 100
Newark, Delaware 19711

Ladies and Gentlemen:

Ladies and Gentlemen:

          We have acted as special counsel to iBio, Inc., a Delaware corporation (the “Company”), in connection with the sale through Further Lane Securities, L.P. as the sales agent from time to time by the Company of shares (the “Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $10,000,000, pursuant to (i) a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on July 26, 2011 (File No. 333-175420) (the “Registration Statement”); (ii) the base prospectus included in the Registration Statement; (iii) a related prospectus supplement filed with the Commission pursuant to Rule 424(b) under the Act (such prospectus supplement and base prospectus described in clauses (ii) and (iii), together, the “Prospectus”); and (iv) that certain At-the-Market Equity Offering Sales Agreement dated as of January 31, 2013 (the “Sales Agreement”) by and between the Company and Further Lane Securities, LP. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares.

          As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.

          Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Sales Agreement, the